Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Innovative strategies in gastrointestinal cancer

Innovative strategies in gastrointestinal cancer editorial memo (2022) 15:1–2 https://doi.org/10.1007/s12254-022-00794-w Gerald Prager Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 Dear reader, date of the leading edge of treatment approaches in gastrointestinal oncology. A series of clinical trials have addressed the impact Ercan Müldür and Wolfgang Hilbe present and dis- and the efficacy of precision medicine (PM) in pa- cuss five emerging studies which have changed stan- tients with gastrointestinal (GI) cancer. PM defines dard of care in esophageal cancer [1]. The manuscript the molecular or immunohistochemical detection of of Aysegül Ilhan-Mutlu and Hannah C. Puhr gives a druggable target in malignant tissue and the sub- a concise overview of new therapeutic options in gas- sequent application of a certain pharmacologic com- tric cancer and recently approved strategies as well pound which—based upon its mode of action—could as ongoing studies [2]. Monika Lenzi and Thomas be expected to modify the course of the underlying Winder discuss the relevance of immunotherapy in GI disorder by interfering with a decisive signal the cell malignancies and provide a perspective on promising uses for sustained growth, proliferation and spread. upcoming treatment strategies [3]. Johannes Schöche Beside drugs http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Innovative strategies in gastrointestinal cancer

Loading next page...
 
/lp/springer-journals/innovative-strategies-in-gastrointestinal-cancer-GzMF6R0Bp8
Publisher
Springer Journals
Copyright
2022 The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-022-00794-w
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2022) 15:1–2 https://doi.org/10.1007/s12254-022-00794-w Gerald Prager Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 Dear reader, date of the leading edge of treatment approaches in gastrointestinal oncology. A series of clinical trials have addressed the impact Ercan Müldür and Wolfgang Hilbe present and dis- and the efficacy of precision medicine (PM) in pa- cuss five emerging studies which have changed stan- tients with gastrointestinal (GI) cancer. PM defines dard of care in esophageal cancer [1]. The manuscript the molecular or immunohistochemical detection of of Aysegül Ilhan-Mutlu and Hannah C. Puhr gives a druggable target in malignant tissue and the sub- a concise overview of new therapeutic options in gas- sequent application of a certain pharmacologic com- tric cancer and recently approved strategies as well pound which—based upon its mode of action—could as ongoing studies [2]. Monika Lenzi and Thomas be expected to modify the course of the underlying Winder discuss the relevance of immunotherapy in GI disorder by interfering with a decisive signal the cell malignancies and provide a perspective on promising uses for sustained growth, proliferation and spread. upcoming treatment strategies [3]. Johannes Schöche Beside drugs

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Feb 1, 2022

Keywords: oncology; medicine/public health, general

References